Although no significant differences in terms of the tumor sizes, number of metastatic lymph nodes, TDSs, BRAF and RAS scores were observed between the subtype CS2 and CS3 (Fig. 6c–g and Supplementary Fig. S8a), they displayed noteworthy opposite trends in the pathway profiles (Fig. 6h, i). This evidence concerns the gene BRAF and neoplasm.